RT Journal Article
SR Electronic
T1 Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21250357
DO 10.1101/2021.04.26.21250357
A1 Anne-Gaëlle Goubet
A1 Agathe Dubuisson
A1 Arthur Geraud
A1 François-Xavier Danlos
A1 Safae Terrisse
A1 Carolina Alves Costa Silva
A1 Damien Drubay
A1 Lea Touri
A1 Marion Picard
A1 Marine Mazzenga
A1 Aymeric Silvin
A1 Garett Dunsmore
A1 Yacine Haddad
A1 Eugenie Pizzato
A1 Pierre Ly
A1 Caroline Flament
A1 Cléa Melenotte
A1 Eric Solary
A1 Michaela Fontenay
A1 Gabriel Garcia
A1 Corinne Balleyguier
A1 Nathalie Lassau
A1 Markus Maeurer
A1 Claudia Grajeda-Iglesias
A1 Nitharsshini Nirmalathasan
A1 Fanny Aprahamian
A1 Sylvère Durand
A1 Oliver Kepp
A1 Gladys Ferrere
A1 Cassandra Thelemaque
A1 Imran Lahmar
A1 Jean-Eudes Fahrner
A1 Lydia Meziani
A1 Abdelhakim Ahmed-Belkacem
A1 Nadia Saïdani
A1 Bernard La Scola
A1 Didier Raoult
A1 Stéphanie Gentile
A1 Sébastien Cortaredona
A1 Giuseppe Ippolito
A1 Benjamin Lelouvier
A1 Alain Roulet
A1 Fabrice Andre
A1 Fabrice Barlesi
A1 Jean-Charles Soria
A1 Caroline Pradon
A1 Emmanuelle Gallois
A1 Fanny Pommeret
A1 Emeline Colomba
A1 Florent Ginhoux
A1 Suzanne Kazandjian
A1 Arielle Elkrief
A1 Bertrand Routy
A1 Makoto Miyara
A1 Guy Gorochov
A1 Eric Deutsch
A1 Laurence Albiges
A1 Annabelle Stoclin
A1 Bertrand Gachot
A1 Anne Florin
A1 Mansouria Merad
A1 Florian Scotte
A1 Souad Assaad
A1 Guido Kroemer
A1 Jean-Yves Blay
A1 Aurélien Marabelle
A1 Frank Griscelli
A1 Laurence Zitvogel
A1 Lisa Derosa
YR 2021
UL http://medrxiv.org/content/early/2021/05/05/2021.04.26.21250357.abstract
AB Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19+), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of non-conventional monocytes and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T helper cells, and non-naive Granzyme B+ FasL+, EomehighTCF-1high, PD-1+CD8+ Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04341207Funding StatementThe Gustave Roussy sponsored clinical study on COVID-19 (ONCOVID; NCT NCT04341207 has been supported by the Fondation Gustave Roussy, the Dassault family, Malakoff Humanis, Agnes b., Izipizi, Ralph Lauren and Sanofi).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided written informed consent. Protocol approval was obtained from an independent ethics committee (ethics protocol number EudraCT No: 2020-001250-21). Gustave Roussy Data Protection Officer (DPO) has evaluated this project and sent to the principal investigator a formalized-operational action plan about data protection compliance: patient's information, security measures, good practices about pseudonymization, etc. All of the DPO's recommendations has been applied by the research team.In agreement with MR004 in France, we reported the series to the national information science and liberties commission. Ethic committees: The Agence Nationale de securite du medicament et des produits de sante (FRANCE) gave the approval for the clinical trial No. EudraCT 2020-001250-21 (reference: MEDAECPP-2020-03-0012). The Committee of the Convention for the Protection of Individuals CPP Ile de France XI (FRANCE) approved the clinical trail (reference: 20025-75647). Decision made: CPP Ile de France XI and Agence Nationale de securite du medicament et des produits de sante authorized Gustave Roussy (No. CSET 2020/3078) for the clinical trial ONCOVID.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and materials availability: This study includes no data deposited in external repositories.Abbreviations in alphabetic orderACE2Angiotensin-Converting Enzyme 2CDcluster of differentiationcMoclassical monocytesCOVID-19severe coronavirus infectious disease 2019CtCycle thresholdCRClinical RoutineCXCR5C-X-C chemokine receptor type 5ECOGEastern Cooperative Oncology Group performance statusEMeffector memory cellsEomeseomesoderminFCfold changeFasLFas ligandGzBgranzyme BHCWhealth care workerICOSInducible T-cell co-stimulatorICUintensive care unitIFNInterferonIgImmunoglobulinILinterleukinLVSlong term viral RNA sheddingNKNatural killernon-cMonon classical monocytesNSMNon-switch MemoryOrf1breplicase open reading frame 1bPDprogressive diseasePD-1programmed cell death 1PMNpolymorphonuclear cellsRBDreceptor-binding domainRdRPRNA-dependent RNA polymeraseRNAribonucleic acidrIL-7recombinant interleukin 7RT-qPCRquantitative reverse transcription-polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2SDstable diseaseSVSshort term viral RNA sheddingTc1cytotoxic T lymphocytesTCF-1Transcription factor 1TFHT follicular helper cellsTRTranslational Research.